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Monoclonal antibodies (MAbs) to rat liver cytochromes P-450 have previously been used for successful im- 
munopurification of cytochromes P-450 from animal tissues. We now report application of this MAb-based 
immunopurification technique to the human lymphoblastoid AHH-1 cell line. Immunopurification carried 
out with 3 different MAbs each yielded a 45-kDa polypeptide. The purified protein contains an MAb-spe- 
cific epitope present on cytochromes P-450, and may therefore be a human cytochrome P-450. 




The cytochromes P-450 metabolize a variety of 
xenobiotic and endobiotic compounds, including 
drugs, carcinogens, and steroids [l-3]. These en- 
zymes are present in multiple forms [4] which 
catalyze reactions that convert these substrates to 
a variety of possible products, including detoxified 
metabolites and toxic or carcinogenic compounds. 
This multiplicity thus far has limited progress in 
the detection and identification of specific 
isozymes in a tissue by conventional methods, 
although the capability to distinguish and measure 
individual P-450s is essential for a variety of 
studies, including those relating the role of in- 
dividual P-450s to metabolism of specific sub- 
strates. 
As an approach to the problem of distinguishing 
closely related isozymes, monoclonal antibodies 
(MAbs) to different P-450s have been prepared 
[5-lo]. The MAbs have thus far proven useful for 
the detection and identification of P-450s by en- 
zyme inhibition assay [ 11,121, radioimmunoassay 
[ 13,141, and immunopurification studies [ 14,151. 
The MAb-based techniques have detected MAb- 
specific P-450s in individual human tissues and 
cells, including lymphocytes [l 11. The cells pre- 
viously examined, however, may have consisted of 
different cell populations which are heterogeneous 
in their P-450 content. Examination of individual 
cloned cell ines for P-450 content should reveal 
the pattern of P-450 expression in individual cells. 
The recently derived AHH-1 cell line possesses 
P-450-dependent monoxygenase activities [ 161. We 
have examined the P-450 in these cells by carrying 
out MAb-directed immunopurifications, proven 
successful for several animal tissues [ 14,151, on 
AHH-I cell extracts. The MAbs used were 
prepared to purified 3-methylcholanthrene (MC)- 
and phenobarbital (PB)-induced rat liver cyto- 
chrome P-450. Three of the MAbs we tested 
specifically extract from solubilized cell extracts a 
45-kDa protein which is putatively a human P-450. 
2. MATERIALS AND METHODS 
AHH-I cells were cultured in RPM1 medium 
1640 supplemented with 5% horse serum (both 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/85/$3.30 0 1985 Federation of European Biochemical Societies 67 
Volume 185, number 1 FEBS LETTERS June 1985 
from Gibco) and maintained in constant exponen- 
tial growth by daily dilution to 4 x 10’ cells/ml 
as described [ 161. They were induced by a 24 h 
pretreatment with 2 pug/ml benz[a]anthracene (BA) 
(Sigma). 
For radiolabeling of cell protein, the cells were 
incubated overnight in the presence of 1 mCi 
[35S]Met (Amersham, 60 Ci/mmol). Cells were 
centrifuged, washed with phosphate-buffered 
saline (PBS), and resuspended in 0.05 M Tris-HCl 
(pH 8.0) to 10’ cells/ml. They were then solubi- 
lized with 0.05 M Tris-HCl (pH 7.5), 0.5 M NaCl, 
1 mM EDTA, 1% 3-(3-cholamidopropyldimethyl- 
ammonia)-1-propanesulfonate (Calbiochem), fol- 
lowed by 30 min incubation at 4°C and centrifuga- 
tion in an Eppendorf microfuge to remove insolu- 
ble matter. The solubilized cell extracts thus ob- 
tained were used for immunopurification studies. 
The MAbs used were 1-7-1 and 1-31-2 to MC- 
induced P-450 [8] and 2-66-3 and 4-7-l to PB- 
induced P-450 [lo]. As a control for nonspecific 
binding, anti-lysozyme HyHel-9 (obtained from 
Dr S. Smith-Gill, NCI) was used. These MAbs 
were purified from mouse ascites fluid and co- 
valently linked to Sepharose as described [14,15]. 
Solubilized cell extracts were then incubated with 
each of the Sepharose-MAb matrices to adsorb 
MAb-specific P-450. After extensively washing the 
resin [ 151, adsorbed protein was eluted with 
0.05 M Tris-HCl (pH 6.8), 2% SDS, and subjected 
to SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE) [17]. Immunopurified proteins were 
visualized by autoradiography. 
3. RESULTS 
AHH-1 cells display P-450-dependent mixed- 
function oxygenase activities that are induced by 
BA treatment [16]. Since MAb-directed immuno- 
purification has been successfully used to prepare 
a variety of cytochromes P-450 from different 
animal tissues and species [ 14,151, we attempted to 
isolate the P-450 present in these cells. Since the 
MAb specificity of the P-450s in these cells was 
unknown, we carried out immunopurifications 
using 4 MAbs to two different rat liver P-450s. 
The SDS-PAGE of proteins immunopurified 
from AHH cells grown in the presence of [35S]Met 
is shown in fig. 1. The whole cell extract has a range 
of radiolabeled proteins (lane 1). Immunopurifica- 
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Fig. 1. SDS-PAGE of 35S-labeled proteins from AHH-1 
cell extracts. Lane 1 contains whole cell extract. Remain- 
ing lanes contain protein immunoabsorbed to Sepha- 
rose-MAb HyHel-9 (lanes 2,3), MAb 1-7-1 (lanes 4,5), 
MAb 4-7-l (lanes 6,7), MAb 1-31-2 (lanes 8,9), MAb 
2-66-3 (lanes 10,ll). Even- and odd-numbered lanes are 
BA-induced and basal cells, respectively. Lane 12 
contains molecular mass markers (96, 67, 45, 32 kDa). 
tion carried out with each of MAbs 1-7-1, 4-7-l 
and 1-31-2 yielded a 45-kDa protein (lanes 4-9). 
The intensity of this band was similar for both 
basal and BA-induced cells. The binding by MAbs 
1-7-1 and 1-31-2 is perhaps not surprising since 
these were prepared to, and are specific for rat 
liver MC-induced P-450 [14], which has aryl 
hydrocarbon hydroxylase (AHH) activity, while 
the AHH activity of these cells suggests they also 
possess a similar AHH-active, MC-inducible 
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P-450. However, the MAb 4-7-1, prepared to the 
relatively AHH-inactive PB-induced rat liver 
cytochrome P-450, also yielded the 45kDa poly- 
peptide. The observation that MAbs to both MC 
and PB-induced P45Os recognize a protein of the 
same Mr in AHH-1 cells thus suggests that these 
cells have a 45kDa protein which is epitopically 
related to these P45Os. 
Immunoadsorption of the 45kDa polypeptide 
by MAbs 1-7-1, l-3 l-2, and 4-7-l is specific since 
with two other MAbs, HyHel-9 and 2-66-3, no ad- 
sorbed polypeptides were observed (lanes 2,3,10, 
11). HyHel-9 is specific for lysozyme, an unrelated 
protein, while 2-66-3 recognizes an epitope on PB- 
induced rat liver P-450. 
4. DISCUSSION 
We have shown that 3 MAbs which recognize 
specific P-450s in PB- or MC-induced rat liver also 
recognize a protein from AHH-1 cells. That this 
protein may be a P-450 is suggested by the observa- 
tion that it contains 3 different epitopes which are 
present on rat liver P-450s. For a single epitope on 
a P-450 to be also present on an unrelated protein 
is unlikely, although possible. For example an 
MAb to streptococci has recently been shown to 
bind myosin as well [ 181. However, the presence of 
3 distinct P4%specific epitopes on an unrelated 
protein is even more improbable. 
Owing to its low level in AHH-1 cells, we have 
only been able to detect this protein when radio- 
labeled with [%]Met, and have been unable to 
otherwise characterize the isolated protein as a 
P-450. When cells were incubated with amino- 
[14~]levulinic acid, a heme precursor, the activity 
of incorporated heme in cellular protein was too 
low for unambiguous autoradiographic identifica- 
tion of any purified heme protein. There is also an 
insufficient quantity of this protein for a reduced- 
CO difference spectrum. 
The intensities of the bands obtained from ex- 
tracts of control and BA-induced cells were simi- 
lar, indicating that the protein we have isolated is 
noninducible by BA. Since BA induces AHH ac- 
tivity about IO-fold [16], whether the isolated pro- 
tein is responsible for AHH activity is unclear, 
although several possibilities exist. First, the 
purified protein may not be responsible for AHH 
activity, and AHH-active P-450s are not purified 
by any of the MAbs under our experimental condi- 
tions; for example, they may bind to MAb relative- 
ly weakly and be removed during the extensive 
washings of the immunoabsorbent. A second 
possibility is that the purified protein may indeed 
be the major P-450 responsible for AHH activity, 
but its level is unaffected by BA; in this instance 
BA treatment might elevate AHH by causing an 
allosteric or other modification in P-450 structure 
to yield a more active form, or by increasing the 
level of a cofactor required for expression of 
activity. 
The putative P-450 we have purified has a 
molecular mass of 45 kDa. This value is relatively 
low compared to that of other P-450s purified 
from animal sources, which have a range of 
48-56 kDa [4], and to that of human P-450s 
isolated from liver [19,20] and placenta [21] which 
also have a molecular mass in this range. Thus, 
whether the molecular mass we observed is typical 
for certain types of human P-450, or is unique for 
the enzyme from lymphoblast cells is not clear at 
present. 
Although an individual cell has the potential to 
express a number of P-45Os, whether each in- 
dividual cell in a population expresses a single 
P-450 or a range of isozymes are expressed is 
unclear. Expression of P-450 is influenced by a 
wide variety of factors and complex regulatory 
mechanisms which are poorly characterized at pre- 
sent. Cloned cell lines in a controlled environment 
provide a system with relatively uniform proper- 
ties for studying the cellular and molecular aspects 
of P-450 regulation. The AHH-1 cell line is 
suitable for such studies, using MAbs to examine 
the P-450 content under various experimental con- 
ditions. This report exemplifies uch a study in that 
it demonstrates that (a) AHH-1 cells produce a 
protein, putatively a P-450, which contains the 
epitopes for 3 different MAbs made to P-45Os, and 
(b) expression of this putative P-450 is not induced 
by BA-treatment. 
Immunopurification as well as other MAb-based 
methodologies can be extended to include other 
MAbs, and thus to characterize the entire range of 
P-450s and other cellular proteins on the basis of 
their interaction with a library of MAbs. Such a 
multidimensional approach should serve to pro- 
vide much useful information in phenotyping 
MAb-defined P-450s in human tissues and cells. 
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